Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...

Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating ...

Chapel Hill-based University of North Carolina Lineberger Comprehensive Cancer Center has been awarded up to $28 million to develop an adaptive clinical trial targeting metastatic breast cancer. The ...

Gastrointestinal-focused CRO Alimentiv is upgrading its clinical trials with software firm PhaseV’s adaptive trial technology. In a new collaboration, Alimentiv will combine PhaseV's machine learning ...

SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...

This year’s agenda has been curated to provide you with the latest innovations, regulatory updates, and strategies on how industry and clinical experts are currently using adaptive designs in their ...

RESTON, Va.--(BUSINESS WIRE)--Aptiv Solutions, a biopharmaceutical and medical device development services company, and the leader in adaptive clinical trial design, simulation and execution, ...

More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- ...

With the introduction of adaptive deep brain stimulation (aDBS) for Parkinson's disease, new questions emerge regarding who, why, and how to treat. This paper outlines the pathophysiological rationale ...

clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial ...